• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Disseminating drug prescribing information: the cox-2 inhibitors withdrawals.传播药物处方信息:环氧化酶-2抑制剂撤市事件
J Am Med Inform Assoc. 2006 Jul-Aug;13(4):396-8. doi: 10.1197/jamia.M2045. Epub 2006 Apr 18.
2
Responding rapidly to FDA drug withdrawals: design and application of a new approach for a consumer health website.对美国食品药品监督管理局(FDA)药品撤市的快速响应:消费者健康网站新方法的设计与应用
J Med Internet Res. 2006 Sep 6;8(3):e16. doi: 10.2196/jmir.8.3.e16.
3
Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.与选择性环氧化酶-2抑制剂相关的史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症报告情况的比较。
Drug Saf. 2005;28(10):917-24. doi: 10.2165/00002018-200528100-00008.
4
Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization.环氧化酶-2(COX-2)选择性抑制剂罗非昔布和伐地昔布的撤市:对非甾体抗炎药及胃保护药物处方和使用的影响
Curr Med Res Opin. 2007 Aug;23(8):1859-66. doi: 10.1185/030079907X210561.
5
Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan.罗非昔布撤市后医师开具环氧化酶-2 抑制剂处方习惯的变化:台湾地区医患配对的回顾性研究。
Clin Ther. 2009 Nov;31(11):2618-27. doi: 10.1016/j.clinthera.2009.11.022.
6
New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra).对塞来昔布(西乐葆)使用的新限制以及伐地考昔(万络)的撤市。
CMAJ. 2005 May 10;172(10):1299. doi: 10.1503/cmaj.050456. Epub 2005 Apr 15.
7
The Internet and drug safety: what are the implications for pharmacovigilance?互联网与药物安全:对药物警戒有何影响?
Drug Saf. 1999 Feb;20(2):95-107. doi: 10.2165/00002018-199920020-00001.
8
Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery.环氧化酶-2抑制剂帕瑞昔布和伐地昔布在接受冠状动脉搭桥手术患者中的疗效与安全性。
J Thorac Cardiovasc Surg. 2003 Jun;125(6):1481-92. doi: 10.1016/s0022-5223(03)00125-9.
9
COX-2 inhibitors--a lesson in unexpected problems.环氧化酶-2抑制剂——一个有关意外问题的教训。
N Engl J Med. 2005 Mar 17;352(11):1131-2. doi: 10.1056/NEJMe058038. Epub 2005 Feb 15.
10
Valdecoxib : the rise and fall of a COX-2 inhibitor.伐地考昔:COX-2 抑制剂的兴衰。
Expert Opin Pharmacother. 2013 Jun;14(8):1077-86. doi: 10.1517/14656566.2013.783568. Epub 2013 Mar 22.

引用本文的文献

1
Responding rapidly to FDA drug withdrawals: design and application of a new approach for a consumer health website.对美国食品药品监督管理局(FDA)药品撤市的快速响应:消费者健康网站新方法的设计与应用
J Med Internet Res. 2006 Sep 6;8(3):e16. doi: 10.2196/jmir.8.3.e16.
2
Approaches to evaluating electronic prescribing.电子处方评估方法。
J Am Med Inform Assoc. 2006 Jul-Aug;13(4):399-401. doi: 10.1197/jamia.M2122.

本文引用的文献

1
Teaching evidence-based medicine: should we be teaching information management instead?循证医学教学:我们是否应该改为教授信息管理?
Acad Med. 2005 Jul;80(7):685-9. doi: 10.1097/00001888-200507000-00014.
2
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.心血管事件风险与罗非昔布:累积荟萃分析
Lancet. 2004;364(9450):2021-9. doi: 10.1016/S0140-6736(04)17514-4.
3
Synergy between publication and promotion: comparing adoption of new evidence in Canada and the United States.出版物与推广之间的协同作用:加拿大和美国新证据采用情况比较
Am J Med. 2003 Oct 15;115(6):467-72. doi: 10.1016/s0002-9343(03)00422-4.
4
Timing of new black box warnings and withdrawals for prescription medications.处方药新黑框警告和撤市的时间安排。
JAMA. 2002 May 1;287(17):2215-20. doi: 10.1001/jama.287.17.2215.
5
Cerivastatin and reports of fatal rhabdomyolysis.西立伐他汀与致命性横纹肌溶解症报告。
N Engl J Med. 2002 Feb 14;346(7):539-40. doi: 10.1056/NEJM200202143460721.
6
Residents' medical information needs in clinic: are they being met?住院医师在门诊的医疗信息需求:这些需求得到满足了吗?
Am J Med. 2000 Aug 15;109(3):218-23. doi: 10.1016/s0002-9343(00)00458-7.
7
Are we providing doctors with the training and tools for lifelong learning?. Interview by Abi Berger.我们是否为医生提供终身学习的培训和工具?。采访者:阿比·伯杰
BMJ. 1999 Nov 13;319(7220):1280. doi: 10.1136/bmj.319.7220.1280.
8
Analysis of questions asked by family doctors regarding patient care.家庭医生提出的有关患者护理问题的分析。
BMJ. 1999 Aug 7;319(7206):358-61. doi: 10.1136/bmj.319.7206.358.
9
The impact of clinical trials on the use of medications for acute myocardial infarction. Results of a community-based study.
Arch Intern Med. 1996 Jan 8;156(1):54-60.
10
Clinical evaluation: how does it influence medical practice?
Bull Cancer. 1987;74(3):333-46.

传播药物处方信息:环氧化酶-2抑制剂撤市事件

Disseminating drug prescribing information: the cox-2 inhibitors withdrawals.

作者信息

Strayer Scott M, Slawson David C, Shaughnessy Allen F

机构信息

University of Virginia Health System, Department of Family Medicine, P.O. Box 800729, Charlottesville, Virginia USA 22908-0729, USA.

出版信息

J Am Med Inform Assoc. 2006 Jul-Aug;13(4):396-8. doi: 10.1197/jamia.M2045. Epub 2006 Apr 18.

DOI:10.1197/jamia.M2045
PMID:16622163
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1513673/
Abstract

This case study examined the recent withdrawal of valdecoxib to determine the timeliness of updates in commonly used information sources used by healthcare professionals. The method included assembling a purposive sample of 15 drug reference and warning systems that were then systematically monitored for several months after the withdrawal of valdecoxib to determine the time to update this information. These information sources were classified and described qualitatively. A time to diffusion curve was plotted and the average number of days to report the drug withdrawal or update reference databases was calculated. Only 2 of 15 information systems reported the drug withdrawal on the actual date of the FDA announcement. Institutional electronic textbooks took an average of 109.8 days (+/-14 days) to report the withdrawal. In addition, one pharma-sponsored dissemination source (Peerview Press) had not updated their information as of this publication.

摘要

本案例研究调查了近期伐地昔布撤市的情况,以确定医疗保健专业人员常用信息来源更新的及时性。方法包括选取15个药物参考和警示系统组成一个有目的的样本,在伐地昔布撤市后对其进行数月的系统监测,以确定更新此信息的时间。对这些信息来源进行了分类和定性描述。绘制了传播时间曲线,并计算了报告药物撤市或更新参考数据库的平均天数。15个信息系统中只有2个在FDA宣布撤市的实际日期报告了该药物撤市。机构电子教科书报告撤市平均用时109.8天(±14天)。此外,截至本出版物发布时,一个由制药公司赞助的传播源(同行评审出版社)尚未更新其信息。